Published online before print January 28, 2002, doi: 10.1161/hc0802.104503
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:975.)
© 2002 American Heart Association, Inc.
Basic Science Reports |
Different Effects of Carvedilol, Metoprolol, and Propranolol on Left Ventricular Remodeling After Coronary Stenosis or After Permanent Coronary Occlusion in Rats
From the First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan.
Correspondence to Yukio Maruyama, MD, First Department of Internal Medicine, Fukushima Medical University, Hikarigaoka 1, Fukushima, 960-1295, Japan. E-mail maruyama{at}fmu.ac.jp
Background— Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO).
Methods and Results— We administered a vehicle, carvedilol, propranolol (2, 10, and 30 mg/kg per day, each), metoprolol (6, 30, and 90 mg/kg per day), or bunazosin (0.2 and 1 mg/kg per day), orally for 12 weeks to a total of 608 rats with CS or CO. In these groups and the sham (n=40), we assessed LV function by echocardiography, CS severity, myocardial blood flow and coronary flow reserve, serum ascorbyl free radical, and vitamin C. Both CS and CO increased LV end-diastolic and end-systolic diameters and decreased ejection fraction. The 4 agents failed to attenuate LV remodeling caused by CO. In contrast, the 3 ß-blockers attenuated (P<0.01) or tended to attenuate the increase in LV end-diastolic diameters caused by CS. With similar blood pressure and heart rate lowering by 3 ß-blockers, carvedilol additionally attenuated the increase in end-systolic diameters and improved ejection fraction. The CS reduced myocardial blood flow and coronary flow reserve, which was reversed by carvedilol without modifying the CS severity. Among the 4 agents, only carvedilol decreased ascorbyl free radical and increased vitamin C.
Conclusions— The effects of ß blockade on ischemic cardiac dysfunction seem to depend on the different properties of the ß-blockers and the doses used. Among the ß-blockers tested, carvedilol provided potent cardioprotection for compromised ischemic but viable myocardium rather than for infarcted myocardium.
Key Words: stenosis • infarction • remodeling • receptors, ardrenergic, beta • ischemia
This article has been cited by other articles:
 |
|
 |
|
  S.-H. Lee, S.-B. Yoon, J.-R. Cho, S. Choi, J.-H. Jung, and N. Lee The Effects of Different {beta}-Blockers on Left-Ventricular Volume and Function After Primary Coronary Stenting in Acute Myocardial Infarction Angiology, January 1, 2009; 59(6): 676 - 681. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Bonnet, N. Laroche, L. Vico, E. Dolleans, C. L. Benhamou, and D. Courteix Dose Effects of Propranolol on Cancellous and Cortical Bone in Ovariectomized Adult Rats J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1118 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Watanabe, H. Yaoita, K. Ogawa, M. Oikawa, K. Maehara, and Y. Maruyama Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol Cardiovasc Res, August 1, 2006; 71(3): 537 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Katritsis Is atrial fibrillation an inflammatory disorder? Eur. Heart J., April 1, 2006; 27(7): 886 - 886. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yaoita, K. Yoshinari, K. Maehara, M. Sando, K. Watanabe, and Y. Maruyama Different Effects of a High-Cholesterol Diet on Ischemic Cardiac Dysfunction and Remodeling Induced by Coronary Stenosis and Coronary Occlusion J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2078 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yoshinari, H. Yaoita, K. Maehara, and Y. Maruyama Different therapeutic responses to treadmill exercise of heart failure due to ischemia and infarction in rats Cardiovasc Res, February 1, 2005; 65(2): 457 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Katritsis Anti-inflammatory medication for atrial fibrillation Eur. Heart J., October 1, 2004; 25(19): 1762 - 1762. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawai, F. Qin, J. Shite, W. Mao, S. Fukuoka, and C.-s. Liang Importance of antioxidant and antiapoptotic effects of {beta}-receptor blockers in heart failure therapy Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1003 - H1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, K. Shioji, Y. Kihara, H. Takenaka, Y. Onozawa, and C. Kishimoto Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H83 - H90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Hamlin, A. Kijtawornrat, B. W. Keene, and D. M. Hamlin QT and RR Intervals in Conscious and Anesthetized Guinea Pigs with Highly Varying RR Intervals and Given QTc-Lengthening Test Articles Toxicol. Sci., December 1, 2003; 76(2): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bello, D. J. Shah, G. M. Farah, S. Di Luzio, M. Parker, M. R. Johnson, W. G. Cotts, F. J. Klocke, R. O. Bonow, R. M. Judd, et al. Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing {beta}-Blocker Therapy Circulation, October 21, 2003; 108(16): 1945 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sato, H. Yaoita, K. Maehara, and Y. Maruyama Attenuation of heart failure due to coronary stenosis by ACE inhibitor and angiotensin receptor blocker Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H359 - H368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishida, T.-S. Li, K. Hirata, M. Yano, M. Matsuzaki, and K. Hamano Improvement of cardiac function by bone marrow cell implantation in a rat hypoperfusion heart model Ann. Thorac. Surg., March 1, 2003; 75(3): 768 - 773. [Abstract] [Full Text] [PDF]
|
|